Pharmaceuticals – Drug Makers Warn of Price Surge Amid Supply Crisis

Pharmaceuticals –  The ongoing conflict in West Asia has begun to significantly strain the pharmaceutical supply chain, triggering a sharp rise in the cost of essential raw materials. Industry stakeholders report that prices of key inputs have surged by as much as 200–300 percent within just two weeks, raising concerns over potential medicine shortages and higher retail prices in the near future.

Production Hubs Under Pressure

Himachal Pradesh, a major hub for pharmaceutical manufacturing in India, plays a crucial role in supplying nearly a quarter of the country’s medicines. The state houses around 650 manufacturing units, many of which are now grappling with reduced access to raw materials and rising operational costs.

Industry representatives have expressed growing alarm over the situation. The Himachal Drug Manufacturers Association (HDMA) has formally appealed to the central government to establish an emergency task force involving industry experts. The association has also called for the immediate enforcement of regulatory provisions under the Essential Commodity Act, 1956 to stabilize the situation.

Raw Material Costs Spike Sharply

According to industry estimates, nearly 40 percent of raw material supplies have been disrupted. Prices of critical components such as active pharmaceutical ingredients, solvents, and packaging materials have risen steeply, making production increasingly difficult to sustain.

One notable example is paracetamol, a widely used pain reliever. Its raw material cost has jumped from ₹250 per kilogram to ₹450 per kilogram in a short span. Manufacturers say they are left with no choice but to procure materials at inflated prices to keep production running.

Reduced Output and Workforce Concerns

The impact of supply shortages is already visible on the ground. Several manufacturing units have scaled down operations, shifting from round-the-clock production to limited eight-hour shifts. This reduction in output has raised fears of job losses and declining productivity across the sector.

Industry leaders warn that if the situation persists, it could severely affect small and medium-sized enterprises, which form a large part of the pharmaceutical ecosystem.

Energy Shortages Add to Challenges

Compounding the issue further are shortages of liquefied petroleum gas (LPG), which is essential for industrial processes such as boiler operations. Domestic LPG shortages are also being reported, potentially leading to workforce migration and further disruptions in manufacturing activities.

These combined challenges threaten to weaken production capacity and disrupt the supply of essential medicines across the country.

Calls for Government Intervention

Manufacturers have urged authorities, including the National Pharmaceutical Pricing Authority (NPPA), to step in and regulate the rising costs of raw materials and packaging inputs. Items such as aluminium, PET, craft paper, and glass bottles have also seen notable price increases, adding to the overall burden on producers.

Industry representatives believe that without timely intervention, the affordability and availability of essential medicines could be at risk.

Retail Prices Likely to Rise

Pharmacists and distributors are also bracing for the impact. Representatives from chemist associations indicate that medicine prices could increase by 20–25 percent in the coming weeks if the supply situation does not improve.

Commonly used medications such as paracetamol, ibuprofen, and diabetes drugs like metformin are particularly vulnerable, as they rely heavily on petrochemical derivatives. Additionally, imported medicines, including certain cancer treatments sourced from the United States and Europe, are expected to become more expensive.

Outlook Remains Uncertain

While there has been no immediate price hike at the retail level, declining inventories and continued supply disruptions are likely to push prices upward soon. Industry experts emphasize that swift policy action will be essential to prevent a wider healthcare crisis and ensure uninterrupted access to affordable medicines.